Analyzing Soleno Therapeutics (NASDAQ:SLNO) and Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL)

Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Profitability

This table compares Pheton Holdings Ltd Class A Ordinary Shares and Soleno Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton Holdings Ltd Class A Ordinary Shares	N/A	N/A	N/A
Soleno Therapeutics	N/A	-61.99%	-55.21%

Valuation & Earnings

This table compares Pheton Holdings Ltd Class A Ordinary Shares and Soleno Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton Holdings Ltd Class A Ordinary Shares	$572,291.00	42.21	N/A	N/A	N/A
Soleno Therapeutics	N/A	N/A	-$38.99 million	($4.26)	-11.65

Pheton Holdings Ltd Class A Ordinary Shares has higher revenue and earnings than Soleno Therapeutics.

Analyst Ratings

This is a summary of current ratings for Pheton Holdings Ltd Class A Ordinary Shares and Soleno Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton Holdings Ltd Class A Ordinary Shares	0	0	0	0	0.00
Soleno Therapeutics	0	0	5	2	3.29

Soleno Therapeutics has a consensus price target of $71.20, indicating a potential upside of 43.46%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Pheton Holdings Ltd Class A Ordinary Shares.

Institutional & Insider Ownership

97.4% of Soleno Therapeutics shares are owned by institutional investors. 12.3% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats Pheton Holdings Ltd Class A Ordinary Shares on 6 of the 9 factors compared between the two stocks.

About Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded on November 2, 2022 and is headquartered in Beijing, China.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.